Although the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is commonly associated with many lung conditions and drugs used for treating them, no literature describes a direct association between SIADH and interstitial lung disease. This case report discusses a 79-year-old male patient who presented to the emergency department (ED) with altered mental status following a fall. The patient had clinical symptoms and imaging findings concerning interstitial lung disease (ILD), and laboratory tests from the ER indicated severe hyponatremia and an increased white blood cell count, suggesting an unusual clinical picture. Detailed workup and medication reconciliation revealed no other medical conditions or intake of drugs associated with SIADH; however, the patient's low serum osmolality, high urine osmolality, high urine sodium, and improvement in serum sodium level with the initiation of 0.9% saline, salt tablets, and tolvaptan verify the presence of SIADH. While the association between SIADH and ILD is not well documented in medical literature, a few case reports from different regions have indicated a potential link, either through drug-induced ILD or SIADH resolution coinciding with ILD improvement. Hence, we describe a case of idiopathic SIADH, possibly associated with interstitial lung disease. This case demonstrates the importance of recognizing the coexistence of SIADH and ILD, as severe hyponatremia can lead to potential life-threatening neurological consequences.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627792PMC
http://dx.doi.org/10.7759/cureus.48304DOI Listing

Publication Analysis

Top Keywords

interstitial lung
16
lung disease
16
siadh
9
syndrome inappropriate
8
inappropriate antidiuretic
8
antidiuretic hormone
8
hormone secretion
8
secretion siadh
8
siadh interstitial
8
disease ild
8

Similar Publications

Background: Baseline lung allograft dysfunction (BLAD) after lung transplant is associated with an increased risk of dying, but the association with health-related quality of life (HRQL) and exercise capacity is not known. We hypothesized that BLAD would be associated with reduced HRQL and 6-min walk distance (6MWD) at 1 y post-lung transplant.

Methods: We analyzed patients who underwent lung transplants in our program from 2004 to 2018 who completed 1-y 36-item Short Form (SF-36) questionnaire and 6MWD testing.

View Article and Find Full Text PDF

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.

Ther Adv Drug Saf

January 2025

Department of Pharmacy, Daping Hospital, Army Medical University, No. 10 Changjiang Branch Road, Yuzhong District, Chongqing 400042, China.

Background: Gilteritinib and midostaurin are FLT3 inhibitors that have made significant progress in the treatment of acute myeloid leukemia. However, their real-world safety profile in a large sample population is incomplete.

Objectives: We aimed to provide a pharmacovigilance study of the adverse events (AEs) associated with gilteritinib and midostaurin through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.

View Article and Find Full Text PDF

Objective: Determine whether pollutants such as fire smoke-related particulate matter smaller than 2.5 microns (PM) are associated with incident rheumatoid arthritis (RA) and RA-associated interstitial lung disease (RA-ILD).

Methods: This case-control study used Veterans Affairs data 10/1/2009-12/31/2018.

View Article and Find Full Text PDF

Purpose Of Review: The purpose of this review is to outline considerations for treating older adults with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) as it relates to infection, comorbidities, cancer, and quality of life.

Recent Findings: The recent 2023 American College of Rheumatology/American College of Chest Physicians guideline conditionally recommended specific disease-modifying antirheumatic drugs (DMARDs), antifibrotics, and short-term glucocorticoids to treat RA-ILD. Since RA-ILD often affects older adults, we contextualize these pharmacologic options related to infection, gastrointestinal (GI) effects, cancer, cardiovascular disease, and quality of life.

View Article and Find Full Text PDF

Challenges of symptom management in interstitial lung disease: dyspnea, cough and fatigue.

Expert Rev Respir Med

January 2025

Respiratory Research @ Alfred, School of Translational Medicine, Monash University, Melbourne, Australia.

Introduction: Interstitial lung disease (ILD) is a broad group of conditions characterized by fibrosis of the lung parenchyma. Idiopathic pulmonary fibrosis (IPF) is the most common subvariant. IPF is marked by considerable symptom burden of dyspnea, cough and fatigue that is often refractory to optimal disease-directed treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!